Hormonal
Tirzepatide produces significantly greater weight loss than semaglutide in overweight and obese adults, with a standardized mean difference of 0.75 favoring tirzepatide.
If you are choosing between tirzepatide and semaglutide for weight loss, current direct comparative evidence suggests tirzepatide may lead to greater weight reduction. This benefit comes with a dual-hormone mechanism (GIP/GLP-1) and requires weekly injections. You should expect potential gastrointestinal side effects during dose increases, which are usually manageable. Combining the medication with diet and exercise will likely enhance results.
The pooled analysis showed greater weight loss with tirzepatide compared to semaglutide (standardized mean difference: 0.75, 95% CI: 0.52 to 0.92).
Why this rating
Meta-analysis of 7 studies (28,980 participants) including RCTs and observational studies, though with high heterogeneity (I² > 90%).
Source
Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies
Nazish Munawar et al. · Cureus · 2025
DOI 10.7759/cureus.86080
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →